نتایج جستجو برای: decompensated cirrhosis

تعداد نتایج: 30534  

Journal: :International Journal of Hepatology 2011

Journal: :Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2016
W Marlicz E Wunsch M Mydlowska M Milkiewicz K Serwin M Mularczyk P Milkiewicz J Raszeja-Wyszomirska

The evidence is mounting that alterations of innate immunity and gut microbiota contribute to chronic liver disease and its complications. Modulation of intestinal microbiota is an emerging therapeutic strategy in hepatology. Probiotics through modulation of intestinal milieu have the potential to affect the course of liver disease. The data concerning the influence of probiotics on various pla...

2014
Matthew E Cramp William M Rosenberg Steven D Ryder Sarah Blach Julie Parkes

BACKGROUND The societal, clinical and economic burden imposed by the complications of chronic hepatitis C virus (HCV) infection - including cirrhosis and hepatocellular carcinoma (HCC) - is expected to increase over the coming decades. However, new therapies may improve sustained virological response (SVR) rates and shorten treatment duration. This study aimed to estimate the future burden of H...

2003
FUTOSHI NAGASAKI YOSHIYUKI UENO TAKESHI YAMAMOTO YU NAKAGOMI OSAMU KIDO EIJI KAKAZU YASUNORI MATSUDA TAKAYUKI KOGURE YOKO YAMAGIWA KUMIKO KIKUCHI KOJI FUKUSHIMA NORIATSU KANNO HIROFUMI NIITSUMA

Received April 6, 2006; revision accepted for publication June 17, 2006. Correspondence: Yoshiyuki Ueno, M.D., Ph.D., Division of Gastroenterology, Tohoku University Hospital, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan. e-mail: [email protected] Sustained Clinical Improvement of a Patient with Decompensated Hepatitis B Virus-Related Cirrhosis after Treatment with Lamivudine Mo...

Journal: :Clinical medicine 2013
Peter Collins Lachlan Ayres Talal Valliani

The likelihood of a general physician encountering a patient with compensated and decompensated liver disease is increasing. This article provides an overview of pharmaceutical agents currently used in the management of cirrhosis and is designed to allow a better understanding of the rationale for using certain drugs in patients with often complex pathology.

Journal: :The New England Journal of Medicine 2021

Infection and increased systemic inflammation cause organ dysfunction death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Whether targeting a serum albumin level 30 g per liter or greater these repeated daily infusions 20% human solution, as compared standard care, ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید